Contract award · W911SR22F0014
CLINICAL DEVELOPMENT PHASE 2 STUDY
Awarded to OLOGY BIOSERVICES, INC. · CAGE 3GQS9
Latest reported total obligated
$93M
Net observed obligations
$93M
Observed contract actions
28
Observed period
FY2022–FY2026
Reported totals are cumulative values from the latest available award record. Observed obligations and actions reflect Mimir's FY2019 onward transaction window and may omit earlier activity.
Award parties and scope
ContractorOLOGY BIOSERVICES, INC.
CAGE3GQS9
Recipient UEIGC2RFAZK8G64
Ultimate parentRESILIENCE GOVERNMENT SERVICES INC
Parent UEIGC2RFAZK8G64
CustomerDepartment of the Army
Performance locationALACHUA, FLORIDA, UNITED STATES
Procurement details
Reported performance startJan 4, 2022
First observed actionJan 5, 2022
Latest observed actionDec 30, 2025
Reported current value$107.9M
Reported potential value$107.9M
PSCAN42
NAICS541715 · Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CompetitionNOT AVAILABLE FOR COMPETITION
PricingCOST PLUS FIXED FEE
SolicitationW911SR22R0040
Annual observed obligations
FY2022
$45.4M
FY2023
$38.6M
FY2024
$23.9M
FY2025
-$14.9M
Continue exploring
Ask Mimir about W911SR22F0014
Continue with this contract award already in context.
ContinueExplore the full award in Mimir
Open the complete action history and connected analysis in the platform.